This invention relates to dihydro-benzo[b][1,4]diazepin-2-one derivatives of the formula
1
wherein R
1
, R
2
, X and Y are as defined in the specification and R
3
is a six-membered aromatic heterocycle containing 1 to 3 nitrogen atoms or a pyridine-N-oxide as further defined in the specification. The invention further relates to medicaments containing these compounds, a process for their preparation as well as their use for preparation of medicaments for the treatment or prevention of acute and/or chronic neurological disorders.
A combination of flow and batch mode processes for the efficient preparation of mGlu2/3 receptor negative allosteric modulators (NAMs)
作者:Raveendra Panickar Dhanya、Ananda Herath、Douglas J. Sheffler、Nicholas D.P. Cosford
DOI:10.1016/j.tet.2018.03.068
日期:2018.6
Benzodiazepinones are privileged scaffolds with activity against multiple therapeutically relevant biological targets. In support of our ongoing studies around allosteric modulators of metabotropic glutamate receptors (mGlus) we required the multigram synthesis of a beta-ketoester key intermediate. We report the continuous flow synthesis of tert-butyl 3-(2-cyanopyridin-4-yl)-3-oxopropanoate and its transformation to potent mGlu(2/3) negative allosteric modulators (NAMs) in batch mode. (C) 2018 Elsevier Ltd. All rights reserved.
BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS
申请人:F. HOFFMANN-LA ROCHE AG
公开号:EP1224175B1
公开(公告)日:2004-03-17
DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS